Body Composition Monitor(BCM) Guided Fluid Management in Maintenance Hemodialysis (MHD) Patients
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jan 12, 2012
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosis of end stage renal disease (ESRD) and need MHD
- • age of 18 years or older but 80 years or less
- • on MHD for at least 3 months
- • dialysis frequency of at least 5 sessions per 2 weeks, not less than 4 hours per session, Kt/V at least 1.2
- • urine volume less than 800mL per 24 hours the day before dialysis session,
- • bioimpedance analysis not used within recent 3 months
- • dry weight regarded as adequate according to the patient's responsible doctor
- • the ability to understand and willingness to sign an informed consent statement.
- Exclusion Criteria:
- • acute infection within 1 month
- • active rheumatic disease, or current on cortical steroid medication or cytotoxic medication
- • uncontrolled neoplasm
- • acute myocardial infarction within 1 month
- • congestive heart failure (NYHA 3 - 4)
- • stroke within 3 months,
- • metallic installation, like contraceptive device, artificial joint(s)
- • amputation
- • female of childbearing age who has a pregnancy plan, or is pregnant, or on breast feeding
- • having a plan to reduce dialysis frequency
- • having a renal transplantation plan or planning to transfer to peritoneal dialysis within 3 years
- • participating or planning to participate another clinical trial, which will confound the current study
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Li Zuo, MD & PhD
Study Director
Institute of Nephrology, Peking University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials